These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15774576)

  • 21. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
    Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
    Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and characterization of Ch806 mimotopes.
    Yang L; Jiang H; Shi B; Wang H; Li J; Wang H; Yao M; Li Z
    Cancer Immunol Immunother; 2010 Oct; 59(10):1481-7. PubMed ID: 20544195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
    Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C
    Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor.
    Johns TG; McKay MJ; Cvrljevic AN; Gan HK; Taylor C; Xu H; Smyth FE; Scott AM
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):572-8. PubMed ID: 20638193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.
    Jungbluth AA; Stockert E; Huang HJ; Collins VP; Coplan K; Iversen K; Kolb D; Johns TJ; Scott AM; Gullick WJ; Ritter G; Cohen L; Scanlan MJ; Cavenee WK; Old LJ
    Proc Natl Acad Sci U S A; 2003 Jan; 100(2):639-44. PubMed ID: 12515857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
    Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
    Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display.
    Chao G; Cochran JR; Wittrup KD
    J Mol Biol; 2004 Sep; 342(2):539-50. PubMed ID: 15327953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
    Lammerts van Bueren JJ; Bleeker WK; Bøgh HO; Houtkamp M; Schuurman J; van de Winkel JG; Parren PW
    Cancer Res; 2006 Aug; 66(15):7630-8. PubMed ID: 16885363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel monoclonal antibodies recognizing the active conformation of epidermal growth factor receptor.
    Ise N; Omi K; Miwa K; Honda H; Higashiyama S; Goishi K
    Biochem Biophys Res Commun; 2010 Apr; 394(3):685-90. PubMed ID: 20226763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downregulation of EGFR by a novel multivalent nanobody-liposome platform.
    Oliveira S; Schiffelers RM; van der Veeken J; van der Meel R; Vongpromek R; van Bergen En Henegouwen PM; Storm G; Roovers RC
    J Control Release; 2010 Jul; 145(2):165-75. PubMed ID: 20362020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor.
    Whitson KB; Whitson SR; Red-Brewer ML; McCoy AJ; Vitali AA; Walker F; Johns TG; Beth AH; Staros JV
    Biochemistry; 2005 Nov; 44(45):14920-31. PubMed ID: 16274239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ligand binding induces a conformational change in epidermal growth factor receptor dimers.
    Walker F; Rothacker J; Henderson C; Nice EC; Catimel B; Zhang HH; Scott AM; Bailey MF; Orchard SG; Adams TE; Liu Z; Garrett TP; Clayton AH; Burgess AW
    Growth Factors; 2012 Dec; 30(6):394-409. PubMed ID: 23163584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation of novel EGFR-specific VHH domains.
    Gottlin EB; Xiangrong Guan ; Pegram C; Cannedy A; Campa MJ; Patz EF
    J Biomol Screen; 2009 Jan; 14(1):77-85. PubMed ID: 19171923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
    Rubin Grandis J; Chakraborty A; Melhem MF; Zeng Q; Tweardy DJ
    Oncogene; 1997 Jul; 15(4):409-16. PubMed ID: 9242377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
    Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
    Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.
    Modjtahedi H; Moscatello DK; Box G; Green M; Shotton C; Lamb DJ; Reynolds LJ; Wong AJ; Dean C; Thomas H; Eccles S
    Int J Cancer; 2003 Jun; 105(2):273-80. PubMed ID: 12673691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.